What to Expect: Merck, Gilead Sciences, and Bristol-Myers Squibb Earnings on Deck
- April 20th, 2025
- 1298 views
Notable companies expected to release their financial results on Thursday, April 24, include:
Merck & Co., Inc. (NYSE: MRK), known for its innovative portfolio of prescription medicines and vaccines, will report its first-quarter 2025 earnings before the U.S. markets open. Analysts expect earnings per share (EPS) of $2.14 on revenue of $15.33 billion. $MRK rose 2.01% (+$1.54) to close at $78.00 on Thursday.
Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company focused on antiviral treatments and oncology, will announce its first-quarter 2025 financial results after market close. Wall Street anticipates EPS of $1.75 and revenue of $6.79 billion. $GILD dipped 0.33% (-$0.35) to finish at $104.53 on Thursday.
Bristol-Myers Squibb Company (NYSE: BMY), a major name in the pharmaceutical space, is set to release its Q1 2025 earnings before the opening bell. The consensus forecast stands at $1.52 EPS on $10.75 billion in revenue. $BMY edged lower by 0.26% (-$0.13), closing Thursday at $49.23.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
October 29th, 2026
Treasury Sanctions Facilitators of DPRK IT Worker Fraud Targeting U.S. Businesses
October 28th, 2026Treasury Sanctions Rwandan Ministry of Defence and Financial Institution Supporting M23
October 28th, 2026October 26th, 2026FAA Releases Draft Design Standards for Vertical Flight Facilities
October 22nd, 2026
Member Login